SUPPORTING INFORMATION

Design, Synthesis, and Biological Evaluation of Indole-Modified Tamoxifen Relatives as Anticancer Agents

Berrak Ertugrul,^a Abdulmelik Aytatli,^{b,c} Omer Faruk Karatas,^{b,c*} Nurullah Saracoglu^{a*}

^aDepartment of Chemistry, Faculty of Sciences, Atatürk University, 25240, Erzurum, Türkiye

^bDepartment of Molecular Biology and Genetics, Erzurum Technical University, Erzurum, 25050, Türkiye

^cMolecular Cancer Biology Laboratory, High Technology Application and Research Center, Erzurum Technical University, Erzurum, 25050, Türkiye

Table of Contents

Comparisons of ¹ H NMR spectra	S2
NOE Experiments	S3
Figures for Cell Viability experiments of final compounds	S4-7
¹ H NMR (400 MHz) and ¹³ C NMR (100 MHz) spectra of compounds	S9-26
HRMS spectra of compounds	S27-32
HPLC trace for final compounds	S33-41

Comparisons of ¹H NMR spectra



Figure S1. Comparison of ¹H NMR spectra of **Z-Tamoxifen** and **Z-26** compounds.

NOE Experiments



Figure S2. Correlations in compound Z-26.



Figure S3. Correlations in compound E-26.

Figures for cell viability of compounds



Figure S4. Cell viability of MCF-7, MDA-MB-231, and MCF10A cells after treatment at different concentrations of TMX. The bar graph represents the mean \pm S.E.M. of four independent experiments. The significance between groups was tested using the Student t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.



MDA-MB-231

MCF-10A

A

MCF-7

and a hard a

24 h

48 h

Figure S5A-D. Cell viability of MCF-7, MDA-MB-231, and MCF10A cells after treatment at different concentrations of TMX indole-derivatives *E*-26, *Z*-26, *E*-33, and *Z*-33. The bar graph represents the mean \pm S.E.M. of four independent experiments. The significance between groups was tested using the Student t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.

Cutton why why who was a server

48 h

24 h

Out of the star of an and an

24 h

the state of the state of the

48 h



Figure S6A-G. Cell viability of MCF-7, MDA-MB-231, and MCF10A cells after treatment at different concentrations of **BIM** *Z,Z*-isomers **35a-g**. The bar graph represents the mean \pm S.E.M. of four independent experiments. The significance between groups was tested using the Student t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.



Figure S7A-G. Cell viability of MCF-7, MDA-MB-231, and MCF10A cells after treatment at different concentrations of **BIM** *E,E*-isomers **35a-g**. The bar graph represents the mean \pm S.E.M. of four independent experiments. The significance between groups was tested using the Student t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.



Figure S8. Cell viability of MCF-7, MDA-MB-231, and MCF10A cells after treatment with IC₅₀ concentrations of 4-OHT and TMX-relative compounds. The bar graph represents the mean \pm S.E.M. of three independent experiments. Significance between groups was tested using Student t-test. * p < 0.05; ** p < 0.01; *** p < 0.001.



Figure S9. Relative expression levels of GREB1 and PS2 genes in MCF-7 cells. The levels of GREB1 and PS2 were normalized to GAPDH. The mean \pm SEM is shown in Figure 6. *p < 0.05, **p < 0.01, ***p < 0.001; t-test.



¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra of compounds



































HRMS spectra of compounds

HRMS spectrum of *E-26*



HRMS spectrum of Z-26



HRMS spectrum of *E*-33



HRMS spectrum of **Z-33**



HRMS spectrum of **Z,Z-35a**



HRMS spectrum of *Z,Z*-35b



HRMS spectrum of *Z,Z*-35c



HRMS spectrum of *Z,Z*-35d



HRMS spectrum of *Z,Z*-35e



HRMS spectrum of *Z,Z*-35f



HRMS spectrum of *Z,Z*-35g



HRMS spectrum of *E,E-*35a



HRMS spectrum of *E,E-*35b



HRMS spectrum of *E,E-35c*



HRMS spectrum of *E,E-35d*



HRMS spectrum of *E,E-35e*



HRMS spectrum of *E,E-35f*







HPLC trace for final compounds

Compound Z-26



PDA				
ID#	Name	Ret. Time	Area	Area%
1	Z-26	8.095	105187792	99.069
2	Impurty1	11.013	329171	0.310
3	Impurity2	11.701	277342	0.261
4	Impurity3	12.204	381705	0.360
Total			106176010	100.000

Compound E-26



PDA				
ID#	Name	Ret. Time	Area	Area%
1	E26	8.417	9424276	95.028
2	Impurity	9.638	493106	4.972
Total			9917382	100.000

Compound **Z-33**



Compound E-33



PDA				
ID#	Name	Ret. Time	Area	Area%
1	E33	5.153	4895245	95.886
2	Impurty1	7.807	210014	4.114
Total			5105260	100.000

Compound Z,Z-35a



Compound **Z,Z-35b**



QuantitativeResult

Compound **Z,Z-35c**



Compound **Z,Z-35d**



PDA					QuantitativeResult
ID#	Name	Ret. Time	Area	Area%	
1	Impurty1	8.318	72500	0.217	
2	Impurty2	9.703	136579	0.410	
3	Z,Z-35d	11.973	33141624	99.373	
Total			33350703	100.000	

Compound **Z,Z-35e**



Compound Z,Z-35f



S37

Compound Z,Z-35g



Compound E,E-35a



Compound E,E-35b



Compound *E,E*-35c



S39

Compound E,E-35d



Compound *E,E*-35e



10#	Name	Ret. Time	Area	Area%	
1	E,E-35E	12.302	4311501	95.948	
2	Impurity1	13.115	182064	4.052	
Total			4493564	100.000	

Compound E,E-35f



Compound *E,E*-35g



PDA					QuantitativeResult
ID#	Name	Ret. Time	Area	Area%	
1	Impurty1	3.868	292914	2.673	
2	E,E-35g	11.126	10663518	97.327	
Total			10956432	100.000	